Daiichi Sankyo Sees Strong Growth Despite One‑Off Costs
Daiichi Sankyo says its underlying business remains strong despite a one‑time expense and conservative earnings guidance that came in below market expectations. The Japanese drugmaker reported double‑digit growth and rising revenue, supported by robust demand for its flagship cancer treatments. The company also outlined its medium‑term outlook, highlighting antibody‑drug conjugates, research investment and the role of artificial intelligence, even as competition intensifies and currency moves remain a factor. Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo, spoke exclusively with Shery Ahn on Insight with Haslinda Amin about results, strategy and growth priorities. (Source: Bloomberg)المصدر: Bloomberg | Source: Bloomberg
ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة Bloomberg. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.
This article was originally published by Bloomberg. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.
